Mayo Clinic (Arizona)

Sorting 13 by

Not yet accepting

SUCCESSOR-1

Phase 3 Clinical Trial Evaluating the Safety and Effectiveness of Investigational Drug Mezigdomide in Combination with Bortezomib and Dexamethasone Compared to Pomalidomide, Bortezomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma
  • CELMoD
  • Randomization
  • Phase 3

Not yet accepting

DREAMM-10

A Phase 3, Randomized, Open-label Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)
  • Antibody Drug Conjugate (ADC)
  • BCMA
  • Phase 3

Accepting patients

CA088-1005

A Phase 1, Multicenter, Open-label Study to Evaluate the Safety and Preliminary Efficacy of BMS-986393 in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma and Determine the Recommended Dose for Each Add-on Investigational Component
  • CAR T Cell
  • CELMoD
  • GPRC5D
  • Phase 1

Accepting patients

GCO12F CAR-T

A Phase 1b/2 Study of GC012F (AZD0120), a Chimeric Antigen Receptor T-cell (CAR T) Therapy Targeting CD19 and B-cell Maturation Antigen (BCMA) in Subjects With Relapsed/Refractory Multiple Myeloma
  • CAR T Cell
  • BCMA
  • CD19
  • Phase 1/2

Accepting patients

Etentamig

A Study to Assess Adverse Events of Intravenously (IV) Infused ABBV-383 in Adult Participants With Relapsed or Refractory Multiple Myeloma
  • Bispecific Antibody
  • BCMA
  • Phase 1
  • Has results

Accepting patients

VSV-hIFNbeta-NIS

VSV-hIFNbeta-NIS in Treating Patients With Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia, Lymphomas, or Histiocytic/Dendritic Cell Neoplasms
  • Phase 1

Accepting patients

Cemsidomide (CFT7455)

Study to Assess the Safety and Tolerability of CFT7455 in Relapsed/Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma
  • IKZF1/3
  • Phase 1/2
  • Has results

Accepting patients

REACH

Combination Treatment Therapy Approaches for the Treatment of High-Risk Multiple Myeloma, REACH Trial
  • Proteasome Inhibitor
  • High Risk
  • Phase 2

Accepting patients

CLN-619

A Phase 1b, Multicenter, Open-Label, Study to Investigate the Safety and Efficacy of CLN-619 (Anti-MICA/MICB Antibody) in Patients With Relapsed and Refractory Multiple Myeloma
  • Monoclonal Antibody
  • Phase 1

Accepting patients

CERVINO

A Phase 3, Multicenter, Randomized, Open Label Study of Etentamig Compared With Standard Available Therapies in Subjects With Relapsed or Refractory Multiple Myeloma (3L+ RRMM Monotherapy Study)
  • Bispecific Antibody
  • BCMA
  • Randomization
  • Phase 3